Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer

Clinical Lung Cancer

Volumn 11, Issue 2, 2010, Pages 114-119

  Grimminger, Peter P ^a   Schneider, Paul M ^b   Metzger, Ralf ^a   Vallböhmer, Daniel ^a   Danenberg, Kathleen D ^c   Danenberg, Peter V ^d   Hölscher, Arnulf H ^a   Brabender, Jan ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Response Genetics Inc   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biomarkers; DFMO; Nontumorous lung tissue; Real time RT PCR; actin

Indexed keywords

MESSENGER RNA; ORNITHINE DECARBOXYLASE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; EARLY CANCER; FEMALE; GENE EXPRESSION; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; SURVIVAL TIME; TUMOR DIFFERENTIATION;

EID: 77952493442     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.015     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975- 2005. National Cancer Institute. Bethesda, MD, 2008. Availabe at: http://seer.cancer.gov/csr/1975-2005/. Accessed: January 25, 2010.
3. Brabender J, Vallbohmer D, Grimminger P, et al. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J Gastrointest Surg 2008; 12:1815-1821
4. Kim YC, Park KO, Kern JA, et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998; 22:181-190
5. Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998; 16:2468-2477
6. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-2291
7. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006; 19:425-432
8. Miao XP, Li JS, Li HY, et al. Expression of ornithine decarboxylase in precancerous and cancerous gastric lesions. World J Gastroenterol 2007; 13:2867-2871
9. Strauss GM, Kwiatkowski DJ, Harpole DH, et al. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 1995; 13:1265-1279
10. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001; 7:1850-1855
11. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002; 235:440-443 (Pubitemid 34183896)
12. Grimminger P, Ling FC, Neiss S, et al. The role of the homeobox genes BFT and CDX2 in the pathogenesis of non-small cell lung cancer. Anticancer Res 2009; 29:1281-1286
13. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982; 243:C212-21.
14. Thomas T, Thomas TJ. Polyamine metabolism and cancer. J Cell Mol Med 2003; 7:113-126
15. Steglich C, Grens A, Scheffler IE. Chinese hamster cells deficient in ornithine decarboxylase activity: reversion by gene amplification and by azacytidine treatment. Somat Cell Mol Genet 1985; 11:11-23.
16. Pohjanpelto P, Holtta E, Janne OA. Mutant strain of Chinese hamster ovary cells with no detectable ornithine decarboxylase activity. Mol Cell Biol 1985; 5:1385-1390 (Pubitemid 15090872)
17. Hirvonen A. Ornithine decarboxylase activity and the accumulation of its mRNA during early stages of liver regeneration. Biochim Biophys Acta 1989; 1007:120-123
18. Beyer HS, Zieve L. Effects of partial and sham hepatectomy on ornithine decarboxylase and thymidine kinase activities and mRNA contents. Biochem Int 1990; 20:761-765
19. Shantz LM, Levin VA. Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids 2007; 33:213-223
20. Pegg AE. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 1986; 234:249-262
21. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984; 53:749-790
22. Pegg AE, Madhubala R, Kameji T, et al. Control of ornithine decarboxylase activity in alpha-difluoromethylornithine-resistant L1210 cells by polyamines and synthetic analogues. J Biol Chem 1988; 263:11008-11014
23. Sistonen L, Holtta E, Lehvaslaiho H, et al. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase. J Cell Biol 1989; 109:1911-1919
24. Auvinen M, Paasinen A, Andersson LC, et al. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992; 360:355-358
25. Hibshoosh H, Johnson M, Weinstein IB. Effects of overexpression of ornithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation. Oncogene 1991; 6:739-743
26. Gazdar AF, Stull HB, Kilton LJ, et al. Increased ornithine decarboxylase activity in murine sarcoma virus infected cells. Nature 1976; 262:696-698
27. Glikman P, Vegh I, Pollina MA, et al. Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer. Cancer 1987; 60:2237-2243
28. Yoshida M, Hayashi H, Taira M, et al. Elevated expression of the ornithine decarboxylase gene in human esophageal cancer. Cancer Res 1992; 52:6671-6675
29. Okuzumi J, Yamane T, Kitao Y, et al. Increased mucosal ornithine decarboxylase activity in human gastric cancer. Cancer Res 1991; 51:1448-1451
30. Upp JR Jr, Saydjari R, Townsend CM Jr, wt al. Polyamine levels and gastrin receptors in colon cancers. Ann Surg 1988; 207:662-669
31. Subhi AL, Tang B, Balsara BR, et al. Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res 2004; 10:7290-7296
32. Tian H, Huang Q, Li L, et al. Gene expression of ornithine decarboxylase in lung cancers and its clinical significance. Acta Biochim Biophys Sin (Shanghai) 2006; 38:639-645
33. Young L, Salomon R, Au W, et al. Ornithine decarboxylase (ODC) expression pattern in human prostate tissues and ODC transgenic mice. J Histochem Cytochem 2006; 54:223-229
34. Love RR, Astrow SH, Cheeks AM, et al. Ornithine decarboxylase (ODC) as a prognostic factor in operable breast cancer. Breast Cancer Res Treat 2003; 79:329-334
35. Brabender J, Lord RV, Danenberg KD, et al. Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J Gastrointest Surg 2001; 5:174-181, discussion 182.
36. Bartholeyns J. Treatment of metastatic Lewis lung carcinoma with DL-alphadifluoromethylornithine. Eur J Cancer Clin Oncol 1983; 19:567-572
37. Klein S, Miret JJ, Algranati ID, et al. Effect of alpha- difluoromethylornithine in lung metastases before and after surgery of primary adenocarcinoma tumors in mice. Biol Cell 1985; 53:33-36
38. Luk GD, Goodwin G, Gazdar AF, et al. Growth-inhibitory effects of DL-alphadifluoromethylornithine in the spectrum of human lung carcinoma cells in culture. Cancer Res 1982; 42:3070-3073 (Pubitemid 12041055)
39. Prakash NJ, Schechter PJ, Mamont PS, et al. Inhibition of EMT6 tumor growth by interference with polyamine biosynthesis; effects of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase. Life Sci 1980; 26:181-194
40. Chang BK, Gutman R, Chou TC. Schedule-dependent interaction of alphadifluoromethylornithine and cis-diamminedichloroplatinum(II) against human and hamster pancreatic cancer cell lines. Cancer Res 1987; 47:2247-2250
41. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159
42. Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000; 4:135-142
43. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6:995-1001.
44. Pike MC. Asymptomatically efficient rank invariant procedures. J R Stat Soc [Ser A] 1972; 135:201-203
45. Miller R, Siegmund D. Maximally selected chi-square statistics. Biometrics 1982; 38:1011-1016
46. Halpern J. Maximally selected chi-square statistics for small samples. Biometrics 1982; 38:1017-1023
47. Abeloff MD, Rosen ST, Luk GD, et al. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer. Cancer Treat Rep 1986; 70:843-845
48. Levin VA, Chamberlain MC, Prados MD, et al. Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. Cancer Treat Rep 1987; 71:459-464
49. Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003; 9:981-990